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Pretrial Drug Testing 
In the 1980's, rising public awareness of 
the drug abuse problem in all sectors of 
society led to a variety of strategies for 
reducing and controlling illicit drug con-
sumption. In the workplace, the military, 
and the criminal justice system, a principal 
strategy has been an increased emphasis on 
the detection of persons who use illegal 
drugs. Since drug users may not show any 
overt symptoms of use and will often deny 
illegal drug use if asked directly, urinalysis 
technologies have emerged as a convenient 
tool for identifying users of illegal drugs. 
.Jiug testing has been used for decades in 
drug abuse treatment programs to monitor 
drug use during treatment. Probation and 
parole agencies in a few States (notably 
California) and in the Federal system have 
had drug testing programs in place for 
more than a decade. In the last several 
years, drug testing has become a common 
requirement during probation or parole for 
From the Director 
In keeping with its congressional mandate, 
the National Institute of Justice (NIJ) is 
committed to a broad research agenda 
involving various means of controlling 
illicit drug use. For example, as part of its 
research and demonstration effon, NIJ's 
Drug Use Forecasting (DUF) program 
monitors drug use among arrestees in 
urban sites across the Nation and chans 
trends that are useful to State and local 
criminal justice officials. 
Pretrial drug testing of arrestees and defen-
dants released pending trial is standard 
procedure in the Washington, D.C., crimi-
nal courts and was implemented for dem-
onstration purposes at six State and local 
criminal court sites. Federal courts are also 
by Christy A. Visher, Ph.D. 
persons convicted of drug offenses or 
suspected of using drugs. 
Drug testing is also gaining the attention of 
national policymakers. The President's 
Office of National Drug Control Policy has 
recommended that State criminal justice 
programs implement comprehensive drug 
testing programs from arrest through 
postconviction supervision.' 
Pretrial drug testing of suspected offenders 
at arrest and during the period before trial, 
however, is a relatively new practice. After 
arrest and arraignment of suspected of-
fenders, judges must make determinations 
of bail and pretrial release and set any 
conditions of release. The principal con-
cern in this decision is the defendant's 
possible flight and potential danger to the 
community. 
The Federal Bail Reform Act of 1984 
urged that a defendant's drug involvement 
considering implementing pretrial drug 
testing in some districts. 
This Research in Brief reviews State and 
local experiences with pretrial drug testing, 
discusses NIJ evaluations that have been 
carried out on cenain testing programs, and 
offers some suggestions for establishing 
such programs. Some important findings 
are that: 
• Drug testing at arrest can be useful to 
judges in making decisions regarding proba-
tion or pretrial release. 
• Drug testing during pretrial release 
permits the courts to supervise drug-
involved defendants more closely and 
be considered in release assessments. 
Washington, D.C., has put this suggested 
policy into practice through one of the 
most comprehensive pretrial drug-testing 
programs in the country. Arrestees are 
asked to submit to a drug test at arrest, and 
those testing positive for illegal drugs may 
be released before trial if they enter a 
monitoring or treatment program involving 
regular drug le ring. 
Both State and Federal criminal justice 
systems are now debating the merits and 
drawbacks of establishing similar pretrial 
testing programs. Among the concerns 
raised about pretrial drug testing are: 
• The utility of the program in reducing 
pretrial rearrests and increasing court 
appearances. 
• The accuracy of the testing procedures. 
• Possible constitutional challenges to 
drug testing at the pretrial stage. 
may reduce the likelihood of pretrial mis-
conduct by some defendants. 
• Implementation of pretrial drug testing 
requires extensive coordination between all 
justice agencies involved. 
NIJ annually conducts evaluations of prom-
ising criminal justice programs and as-
sesses the usefulness and effectiveness of 
advances in technology as pan of its mis-
sion tu control drug abuse and improve the 
justice system. An imponant part of the 
Institute's goal is the publication of docu-
ments such as this that inform criminal 
justice professionals across the Nation. 
Charles B. DeWitt 
Director 
National Institute of Justice 
~~~~~~~~~~~HV5823.5 .U65 1992 
visher, Christy Ann 
Pretrial drug testing 
• The costs associated with operating a 
pretrial testing program. 
A series of studies funded by the National 
Institute of Justice (NIJ) and the Bureau of 
Justice Assistance (BJA) provide empirical 
and practical information about the utility 
of pretrial drug testing. Drawing on these 
studies, this Research in Brief discusses the 
current research and policy debates on 
pretrial drug testing. 
Pretrial drug testing in 
Washington, D.C. 
Pretrial drug testing has existed in Wash-
ington, D.C., since the 1970's. The original 
program referred suspected drug-involved 
offenders to a local treatment agency 
which conducted the tests and delivered 
the results to the courts. In 1984, this test-
ing program was transferred to the criminal 
justice system, and the Pretrial Services 
Agency (PSA) of Washington launched an 
expanded, comprehensive program for all 
arrestees and all released drug-involved 
offenders. 2 
The new program was based on research 
that has consistently shown that the most 
frequent serious offenders are also the 
heaviest drug users. Moreover, for many 
drug-involved offenders, criminal activity 
appears to rise or decline with level of drug 
use, especially of heroin and cocaine.3 In 
practical terms, the identification of drug-
involved offenders and potential control of 
their drug use appeared to be a useful 
approach to managing high-risk defendants 
at the earliest stage of the criminal justice 
process. 
The pretrial testing program in the District 
of Columbia has two components: ( 1) 
detection of drug use by testing arrestees 
prior to the initial court appearance and 
release decision, and (2) monitoring drug 
use among released defendants by regular 
testing as a condition of release. Testing of 
arrestees in a facility within the courthouse 
is completed before arraignment, and 
results are available to the judge before the 
initial court appearance. PSA uses the 
EMIT™ (enzyme multiplied immunoassay 
test) and screens arrestees for five drugs-
cocaine, opiates (primarily heroin), PCP, 
methadone, and amphetamines. The initial 
drug test is voluntary, but compliance is 
high because judges will often deny non-
financial release to those who refuse test-
ing. Test results are not used in prosecution 
or adjudication decisions. 
In most State and Federal courts, judges 
may set release conditions to minimize the 
safety threat posed by high-risk defendants 
and to ensure appearance at trial. The 
second component of the Washington 
testing program, drug monitoring during 
release, provided judges with a new option 
for handling drug-involved offenders in the 
period before trial. Arrestees who test 
positive for drugs at arrest are placed in a 
regular drug testing or treatment program 
as a condition of release. 
Defendants must report at least weekly for 
testing; all tests are recorded into an auto-
mated information system. Violations 
(positive tests or nonappearance for test-
ing) are met with a system of graduated 
sanctions, including more frequent testing, 
detention for 3 to 5 days, and, in extreme 
cases, incarceration until trial. Some judges 
use performance in the monitoring pro-
gram in sentencing convicted defendants. 
Evaluations of the 
Washington testing program 
It was hoped that the Washington program 
would provide D.C. criminal justice offi-
cials with objective information about drug 
use. Such information would then be used 
in pretrial release decisions as an addi-
tional consideration in assessing defendant 
suitability for release. D.C. officials also 
hoped that a pretrial monitoring program 
might help control drug use among re-
leased defendants, which in tum might 
lead to reductions in pretrial misconduct-
either rearrest or failure to appear (FT A). 
One comprehensive evaluation and several 
other analyses examined whether the 
program was accomplishing these two 
objectives in its first 2 years of operation 
(1984-1986). 
Persons who tested positive for drugs at 
arrest were more likely to be rearrested and 
miss scheduled court appearances than 
nondrug users, according to data from the 
program. Indeed, the likelihood of rearrest 
in the early weeks after release was about 
four times higher for drug users than 
nonusers, even after taking into account 
defendant attributes usually associated 
with pretrial rearrest. Moreover, the results 
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, 
of the drug test at arrest appeared to add 
significantly to the likelihood of pretrial 
misconduct, over and above typically 
collected information on defendant's em-
ployment, prior convictions, and pending 
case status. In particular, multiple drug use 
increased the likelihood of pretrial rearrests 
and missed court appearances.4 
Thus in Washington, drug test results seem 
to improve a judge's ability to assess reli-
ably the likelihood of a defendant's pretrial 
misconduct. But does regular testing re-
duce rearrest and FT A rates for all released 
drug users? An experimental evaluation of 
the effects of the monitoring program, in 
which eligible defendants were randomly 
assigned to either regular drug testing, 
community drug treatment, or a control 
group, found no differences among the 
three groups in rearrest or FT A rates. This 
type of evaluation is the strongest statisti-
cal test of whether regular drug testing 
during release might reduce pretrial mis-
conduct. However, such experiments are 
difficult to carry out successfully in an 
operational criminal justice setting, and 
implementation problems in carrying out 
the study in Washington may have com-
promised the experimental design. 
The evaluation did find that about two-
thirds of defendants assigned to drug moni-
toring during release stayed with the 
program for at least three tests. These 
defendants had lower rates of rearrest and 
failure to appear than those who never 
showed up for testing or who dropped out 
of the program before the third test. More-
over, another study of the program found 
that pretrial misconduct was especially 
high among defendants who did not report 
for their first postrelease test. However, it 
is difficult to determine whether the moni-
toring program encouraged good behavior 
or whether the group of released drug users 
who showed up for testing would have 
been low risks without the program. 
Overall the study showed that some drug 
users had a better chance of success than 
others, and that a monitoring program may 
help to sort out the good and bad prospects 
by allowing these drug users to "signal" 
their cooperation to the court through the 
testing program. However, a small group 
of drug users did not comply with the 
program. Their noncompliance was a 
strong indicator of their high propensity for 
pretrial rearrest and FT A. 
rlesearch in Manhattan 
and Miami 
Independent research in Manhattan in 1984 
and Miami in 1987 provides additional 
information on whether drug tests at arrest 
might provide information on defendant 
potential for pretrial rearrest or Ff A. Pre-
trial testing programs were not operational 
in these sites, but both jurisdictions were 
considering the implementation of testing 
programs and allowed researchers to 
gather data, including the results of volun-
tary drug testing at arrest, on defendants 
being considered for release. Since these 
were exploratory studies, judges were not 
informed of the test results, and defendants 
were assured that the results would only be 
used for research. 
In both sites, released defendants who 
tested positive for illegal drugs had higher 
rates of pretrial misconduct than defen-
dants similar in all other respects. In Man-
hattan, both pretrial rearrest and failure to 
appear rates were higher among those 
testing positive, especially for those testing 
positive for more than two drugs.5 But a 
·eparate analysis of the Manhattan data 
.:oncluded that urine testing was not a 
feasible policy alternative, because drug 
test results did not measurably improve 
the ability to assess the likelihood of an 
individual's failure to appear.~ 
In Miami, drug test results were statisti-
cally related to later pretrial rearrest, espe-
cially rearrest for serious crimes, but not to 
failure to appear.7 Some drug-specific 
Research and Evaluation 
Study Sites 
Original (Prototype) Site 
Washington, D.C. 
Demonstration Sites 
Prince George's County, Maryland 






Other Research Sites 
Manhattan, New York 
Miami, Florida 
Exhibit 1 
Common implementation problems encountered 
in pretrial testing programs 
• Inability of sites to test the majority of arrestees for illegal drug use at the time 
of arrest. 
• Lack of support among pretrial staff in recommending eligible defendants for 
the monitoting program. 
• Failure to provide the arraignment judge with initial drug test results before 
the hearing. 
• Low referral rate to the monitoring program for eligible defendants by 
arraignment judge. 
• High rates of noncompliance (no-shows) for testing among the released 
defendants in the monitoring program. 
• Difficulty in maintaining current information about test results, sanctions 
pending, etc., for defendants in the monitoring program. 
• Lack of judicial support for sanctioning plan, which led to high violation rates 
(no-shows and positive tests) among defendants in the testing program. 
results also existed (for example, PCP use 
affected rearrest in Manhattan, but not 
Ff A), but no clear patterns emerged in the 
two jurisdictions. However, differences in 
these studies' results are not surprising 
given the strong contrasts between the sites 
and the changing nature of drug use during 
the years of the studies.K 
In summary, drug test results appear to 
help the classification of defendants ac-
cording to potential for pretrial misconduct 
in three sites-Washington, D.C.; Manhat-
tan; and Miami-but do not necessarily 
guarantee improvement in specific predic-
ti(ms. For example, in the Manhattan study 
of 100 released defendants testing positive 
for PCP, 37 could be expected to be 
rearrested. Analysts comparing 100 non-
PCP users, similar in all other characteris-
tics, expected 25 to be reaJTested. 
Then identifying which PCP user would be 
rearrested is much more difficult. Deter-
mining whether drug test results would aid 
in making such predictions re4uires differ-
ent analyses than those used in existing 
studies. 
Replications of the 
Washington program 
In an effort to gain fw1her insight into 
whether pretrial testing programs would be 
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useful in other jurisdictions, BJA funded 
six sites to implement programs modeled 
on the one in the District of Columbia (see 
accompanying list). BJA funded evalua-
tions of four of these programs, and NIJ 




All six demonstration sites experienced 
varying levels of difficulty in implement-
ing a pretrial drug testing program (see 
exhibit 1 ). In two sites problems could not 
be resolved in time for the evaluation. In 
general, the practical problems of imple-
menting pretrial drug testing programs 
were related to supp011 for the program 
within the local criminal justice commu-
nity and the relevant agencies, and logistic 
capability of the jurisdiction to implement 
the program. 
Legal considerations arose in the planning 
stage in several demonstration sites, al-
though none seriously impeded the imple-
mentation of the programs. 
Some sites were able to correct most prob-
lems as the programs continued (in some 
cases, after the evaluation was completed), 
but the quality of the data collected during 
the early phase of the programs was clearly 
affected by implementation problems. 
Issues of system support 
Implementation of a pretrial testing pro-
gram modeled after the Washington, D.C., 
program demands involvement of all agen-
cies within a local criminal justice system. 
The pretrial services agency often must 
coordinate its efforts with the police or 
sheriff's department that detains the 
arrestees before testing. In Milwaukee, 
program implementation was delayed until 
the police department consented to drug 
testing of arrestees who were being held 
until arraignment. 
In Prince George's County, Maryland, bail 
magistrates at local police stations released 
40 percent of eligible defendants on cash 
bail before testing could occur. These 
defendants were not considered for non-
financial supervised release; hence, they 
Ways of Coping With 
Implementation of Pretrial 
Drug Testing Programs 
Consider modifications in existing 
bail release and pretrial screening 
procedures to expand identification of 
drug users who could be eligible for 
pretrial release using the drug moni-
toring program. 
Involve pretrial agency personnel in 
the development of the program. 
Coordinate procedures for drug test-
ing at arrest with police and/or 
sheriff's department personnel. 
Obtain necessary expertise to de-
velop and maintain an information 
and tracking system for released 
defendants prior to program 
implementation. 
Involve bail magistrates and arraign-
ment judges in program development, 
including development of sanctioning 
plan for violations of pretrial release 
conditions. 
Choose a location convenient to de-
fendants for the drug testing center. 
Allow sufficient time for an imple-
mentation period before collecting 
data for program evaluation. 
could not be placed in the monitoring 
program. 
Other problems surfaced when private 
agencies with important roles in the pre-
trial release system were involved. Initially 
in Phoenix, few arrestees agreed to be 
tested; it was later determined that a pri-
vate agency that was interviewing arrestees 
was not correctly explaining the nature of 
the pretrial testing program. 
In Portland, one private agency inter-
viewed and tested arrestees before the 
release hearing, and three other agencies 
(public and private) supervised released 
defendants. Difficulties in coordinating the 
efforts of these organizations led to con-
siderable interagency diversity in imple-
mentation and to problems in tracking 
defendants during release. 
Support from the judiciary was particularly 
crucial to the implementation of the pro-
gram. Judges were supposed to use drug 
test results in determining pretrial release, 
assigning eligible drug users to the drug 
monitoring program, and imposing sanc-
tions on defendants who failed to comply 
with the monitoring program. Although the 
chief judge or magistrate in all demonstra-
tion sites had approved the program, indi-
vidual judges in some sites apparently did 
not support the program's goals. Thus in 
some sites, relatively few eligible defen-
dants were referred to the monitoring 
program, and sanctions for program viola-
tions were not consistently carried out. 
In Portland, when it became apparent that 
judges were not using the program as a 
release condition, the chief judge issued a 
court order directing referral to the moni-
toring program as a condition of release for 
eligible defendants. Program referral rates 
improved dramatically. 
Issues of logistics 
Logistic problems in implementing the 
pretrial testing program in a few sites 
proved as serious as system support prob-
lems. Among the most common problems 
were (I) integrating the program within an 
existing structure of pretrial release proce-
dures; (2) creating a computerized infor-
mation system to allow efficient tracking 
of defendants and the collection of data for 
the evaluation; (3) locating a convenient 
testing facility accessible to defendants 
during release; (4) informing new and 
rotating pretrial personnel and judges 
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about the testing program and its opera-
tions; and (5) scheduling court hearings for 
defendants who did not comply with the 
testing program. Solving such logistic 
issues requires the involvement of many 
different agencies whose actions must 
be coordinated (see box "Ways of 
Coping ... "). 
In most sites, one or more of these imple-
mentation problems seriously affected the 
collection of data necessary for an ad-
equate evaluation of the pretrial testing 
program. But in Wilmington, Delaware, 
the problems encountered in commencing 
and managing the program ·were so pro-
found that the program was never fully 
implemented, and Federal funds for pro-
gram operation and evaluation were 
terminated. 
In Portland, the program eventually over-
came most of the implementation prob-
lems, but the data collected were 
insufficient for a reliable evaluation. 
Results of the evaluations 
In four of the six sites, the evaluators were 
able to collect the necessary data for an 
assessment of whether the program was 
meeting its stated goals. Recall that the two 
questions at issue were (l) whether drug 
abuse detection at arrest (using urinalysis) 
might provide additional information about 
the likelihood of pretrial rearrest or FT A 
for released defendants, and (2) whether 
drug use monitoring (regular urinalysis) 
during release might reduce pretrial 
rearrest and FT A. 
In two of these four sites, defendants who 
tested positive for illegal drugs at arrest 
were at significantly greater risk of pretrial 
rearrest or FT A, after taking into account 
factors usually considered by the arraign-
ment judge. In Milwaukee and Phoenix, 
positive drug test results increased risk of 
FTA and rearrest, respectively. 
As to the evaluation of the drug monitoring 
component, again, two of the four sites 
concluded that the program significantly 
reduced rearrest (Tucson) or FTA (Phoe-
nix). However, the program's impact was 
not large, and the evaluators concluded 
that the program had only modest effects 
on pretrial misconduct. 10 
These evaluation results, however, must be 
interpreted in light of the operational diffi-
culties experienced. The implementation 
exhibit 2 
Research and evaluation results of pretrial drug testing programs 
Site Drug testing at arrest Monitoring programs 
for releasees 
Washington, D.C. Predicted pretrial Did not reduce 
rearrests and Ff A's rearrests or FfA's 
Phoenix Predicted pretrial Reduced Ff A's, but 
rearrests, but not FfA's not rearrests 
Tucson Did not predict Reduced rearrests, 
rearrests or FfA's but not FfA's 
Milwaukee Predicted Ff A's but Did not reduce 
not pretrial rearrests rearrests or Ff A's 
Prince George's Did not predict Did not reduce 
County rearrests or Ff A's rearrests or Ff A's 
Portland Insufficient data Insufficient data 
Wilmington Insufficient data Insufficient data 
Miami Predicted pretrial Not implemented 
rearrests, but not Ff A's 
Manhattan Predicted pretrial 
rearrests and Ff A's 
problems discussed earlier reduced the 
quality of the evaluation data in several 
sites. Consider those sites which. only 
tested half of the eligible defendants at 
arrest. If, for example, the defendants who 
refused the test were more likely to be at 
risk for pretrial misconduct than those who 
agreed to be tested, then the evaluation 
results were based on a relatively low-risk 
group; and it is not surprising that the drug 
test results did not enhance assessment of 
pretrial misconduct. 
As another example, in sites which had 
low rates of referral to the monitoring 
program of eligible defendants (who may 
have differed in important respects from 
defendants not referred), the experimental 
evaluation cannot effectively assess the 
program's impact on pretrial misconduct 
for the total eligible population. 
loreover, serious anomalies in some of 
the statistical analyses make valid interpre-
tation of the results highly questionable. 11 
Small sample sizes, especially for the 
Not implemented 
experimental evaluation of the monitoring 
program, also hindered convincing analy-
ses in several of the sites. It is also dif-
ficult to compare the evaluation results 
across sites because of different analytic 
procedures. 
Assessing the utility of 
pretrial drug testing 
Studies from nine jurisdictions (Washing-
ton, Miami, Manhattan, and the six demon-
stration sites) have examined the practical 
utility of pretrial drug testing for release 
decisions or pretrial supervision of drug-
involved offenders (see exhibit 2). In five 
of the seven sites that collected data on 
release decisions, drug test results provided 
additional information about the defen-
dant's likelihood of rearrest or Ff A, but 
not always about both types of misconduct. 
Thus, drug tests at arrest are likely to be 
useful in pretrial release decisionmaking, 
but drug test results may not be equally 
5 
predictive of rearrest and Ff A in all 
jurisdictions. 
Less encouraging were the evaluation 
results of the second component of the 
pretrial testing program. The drug monitor-
ing program for released drug users only 
reduced rearrests or FfA's (and these were 
modest effects) in two (Tucson and Phoe-
nix) of the five jurisdictions that imple-
mented the monitoring experiment. 
But the demonstrations showed that even 
though regular drug testing during 
release may not decrease pretrial miscon-
duct for all released drug users, some 
drug-involved offenders may benefit from 
the program. In three demonstration sites 
(Tucson, Prince George's County, and 
Milwaukee), a sizable group of released 
drug users consistently tested negative 
while in the monitoring program: About 30 
percent or more of those assigned to regu-
lar drug testing during pretrial release did 
not test positive for drug use during the 
monitoring program. For example, in 
Tucson, 29 percent of defendants in the 
monitoring program had no positive tests 
during monitoring. In Prince George's 
County 36 percent had no positive tests 
during monitoring, and in Milwaukee 32 
percent had no positive tests. This group of 
drug-involved offenders may simply have 
been casual, infrequent drug users, or the 
enforced nature of the program may have 
deterred them from illegal drug use while 
awaiting trial. 
Other data suggest that compliance with 
drug monitoring programs may serve as an 
early warning system for pretrial miscon-
duct among released drug users. This sig-
naling effect described by the evaluators of 
the Washington program appeared to have 
some support in three sites that reported 
detailed data on defendant performance in 
the monitoring program. 
For example, in Tucson, defendants with 
no more than two positive tests during 
monitoring were rearrested or missed court 
appearances less often than defendants 
with at least three positive tests or those 
who did not appear for testing at all (see 
exhibit 3). Similar patterns were found in 
Milwaukee and Prince George's CountyY 
Thus, a pretrial drug monitoring program 
can be a useful strategy for supervising 
some offenders. Pretrial drug testing may 
reduce drug use, and perhaps related 
criminal activity, for some released drug-
Exhibit 3 
Pretrial misconduct and defendant behavior in drug monitoring 
program: Tucson, Arizona 
Positive Number of Percent with 
test results cases rearrests or Ff A's 
None 45 8.8 
1-2 37 10.8 
3-9 35 28.6 
6 a lOormore -
Missed all tests 30 50.0 
Total of all defendants 153 15.0 
Source: Tabulated from data presented in Michael Gottfredson et al., Evalua~ion of 
Arizona Pretrial Services Drug Testing Programs, Final Report, National Institute of 
Justice, 1990: 41-42. 
• Too few cases to compute a meaningful percentage. 
involved offenders. Moreover, as a super-
visory tool the monitoring program pro-
vides the courts with reliable information 
about the behavior of drug-involved of-
fenders during pretrial release. 
Future of pretrial drug testing 
Expanding in D.C. 
Although the pretrial drug testing program 
in the District of Columbia also faced 
some of the problems that the demonstra-
tion sites experienced, these problems were 
eventually resolved. Most judges and 
hearing commissioners in Washington 
responded in interviews that they use the 
information generated from the testing 
program a great deal and that it represents 
a substantial improvement over previous 
practices. 13 Judges in the District of Co-
lumbia believe that accurate information 
about drug use is vital to their decisions 
regarding pretrial release and supervision 
of released drug-involved offenders. 
The Washington program was recently 
expanded to include testing of juvenile 
offenders. 
Overcoming obstacles elsewhere 
Pretrial drug testing programs present 
many challenges to other jurisdictions 
considering their implementation. At least 
two obstacles to such programs, however, 
have largely disappeared: concerns about 
the accuracy of drug tests and associated 
legal issues. 
Despite some claims to the contrary, im-
munoassay urinalysis technologies are 
widely regarded as very accurate, 14 and the 
accuracy of the most commonly used test 
in criminal justice operations, EMIT, has 
been upheld in numerous court decisions. 15 
A recent study by NIJ and BJA evaluated 
the accuracy of four commonly used drug 
testing urinalysis technologies. 16 The study 
concluded that immunoassays are much 
more accurate than thin-layer chromatog-
raphy (commonly used in the 1970's). 
Drug testing using immunoassay methods 
correctly identifies 98 to 99 percent of 
negative urine specimens (i.e., few "false 
positive" results) and correctly identifies 
about 80 percent of positive urine speci-
mens (i.e., moderate "false negative" re-
sults). The study recommended that 
positive results be confirmed by a highly 
accurate method if the test result is con-
tested by the defendant and could be used 
as the basis for punitive action. 
Several legal issues concerning the consti-
tutionality of pretrial drug testing were 
discussed at length in most of the demon-
stration sites. Among the issues raised 
were: do pretrial drug tests violate 4th 
amendment protections against unreason-
able searches, 5th amendment guarantees 
6 
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against self-incrimination, or 14th amend-
ment protections pertaining to equal pro-
tection and substantive and procedural due 
process requirements? Two recent legal 
analyses of the existing case law disagree 
as to whether pretrial drug testing may 
withstand these constitutional challenges. 17 
Nonetheless, the constitutionality of volun-
tary testing of arrestees before arraignment 
has not come before the courts during the 
program's operation in Washington, D.C. 
As of this writing, there are no pending 
legal challenges to pretrial drug testing in 
either State or Federal courts. 
More serious potential obstacles to pretrial 
drug testing are the problems that can arise 
in the actual implementation of a program. 
Resolving these problems can spell the 
difference between a successful program 
and an unsuccessful one. Internal and 
external support for pretrial testing is criti-
cal to its effectiveness. The introduction of 
a new operation into an existing system of 
procedures often meets with resistance, 
and building support among staff involved 
in the implementation of a pretrial testing 
program is essential to its success. Gaining 
the support of the judiciary is particularly 
important. 
The successful operation of pretrial drug 
testing programs is also dependent on other 
local circumstances. 
Jurisdictions vary widely in patterns of 
criminal behavior and drug use, and these 
differences may affect how such programs 
are best used. For example, jurisdictions 
with small criminal caseloads, such as 
Wilmington, may not benefit as much 
from program implementation as a juris-
diction with a greater caseload. 
As another example, Tucson experienced 
very low rates of pretrial misconduct dur-
ing the evaluation phase of the project. If 
such low rates are typical, then a large-
scale drug monitoring program may not be 
able to improve defendant behavior on 
release sufficiently to justify its costs. 
However, the drug detection component of 
the program might be useful for tracking 
drug use in the offender population, iden-
tifying drug-involved offenders, and en-
couraging drug positive arrestees to seek 
treatment. 
Conversely, jurisdictions with high rates of 
drug use among the arrestee population 
may find that initial drug test results cannot 
,nificantly help make release decisions 
masmuch as the vast majority of arrestees 
will test positive for drug use. In this situa-
tion, the detection component might be 
used to identify multiple drug users (those 
at highest risk if released), and a drug 
monitoring program might help the super-
vising agency more closely monitor the 
behavior of drug users who are released 
before trial. Moreover, as some of the 
demonstration programs showed, about 
one-third of those who tested positive for 
illegal drugs at arrest had no positive tests 
while in a drug monitoring program. 
For many drug-involved offenders, reduc-
tions in drug use may lead to reductions in 
criminal activity. More research is needed 
on identifying the characteristics of those 
drug-involved offenders who might benefit 
from drug monitoring during release. 
Costs associated with pretrial drug testing 
programs also vary with local circum-
stances. Particular policy and procedural 
decisions about the program, such as staff-
ing patterns, choice of testing equipment, 
number of drugs tested, and size of target 
""'!Jpulation, can substantially affect operat-
5 costs. For example, these types of 
tactors resulted in more than a threefold 
difference in estimated first-year costs for 
operating both components of a pretrial 
testing program in two jurisdictions with 
the same annual arrestee population. 18 
Future studies 
As more jurisdictions implement pretrial 
drug testing programs, more will be 
learned about how and under what circum-
stances pretrial testing can improve the 
management of drug-involved defendants 
in the community. A 1990 nationwide 
survey of State and local pretrial services 
programs found that 72 programs were 
conducting pretrial testing at some level, 
usually selectively, as a condition of re-
lease.19 However, research on their effec-
tiveness is needed. 
In 1992, NIJ will be conducting an inten-
sive analysis of pretrial testing programs, 
including an assessment of programs that 
have recently become fully operational. 
'onclusion 
In making decisions about implementation 
of pretrial drug testing programs, policy-
makers and criminal justice officials 
must weigh all of these considerations-
expected utility, implementation issues, 
local circumstances, value to the commu-
nity, and costs. 
Information gained from pretrial testing 
can also be useful for detecting drug use 
among arrestees, assessing drug treatment 
needs, tracking local changes in drug use 
preferences, and documenting need for 
State and Federal assistance for drug en-
forcement and treatment programs. Pretrial 
testing, both at arrest and during release, is 
also one component of the comprehensive 
drug testing program recommended by 
the President's Office of National Drug 
Control Policy. 
Many criminal justice officials are uncer-
tain about whether pretrial drug testing 
would be useful for their jurisdiction. But 
much of this uncertainty is based on misin-
formation or lack of information about the 
operations, practicality, and utility of pre-
trial drug testing. This paper attempts to 
illuminate some of these issues. Neverthe-
less, it is also apparent that pretrial drug 
testing will fail when local criminal justice 
officials have not adequately planned for 
its implementation. Officials involved in 
ongoing pretrial testing programs and other 
experts can provide practical information 
and technical assistance in designing 
programs. 
As a first step, testing of arrestees can 
provide valuable information about the 
nature and extent of drug use among the 
offender population, which can be used in 
planning both comprehensive drug testing 
and treatment programs. This type of ap-
proach would probably be a suitable initial 
stage for most jurisdictions and could be 
modeled after NIJ's Drug Use Forecasting 
program. Drug testing as a supervision 
tool, whether during pretrial release or as a 
postconviction option, requires consider-
able additional planning, and favorable 
outcomes may require a year or more of 
cooperative effort. 
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